Joshua M. Steinberg, MD (@joshsteinbergMD) header
Joshua M. Steinberg, MD (@joshsteinbergMD) profile picture

Dir. of IBD @gastrorockies | Clinical Instructor @CUMedicalSchool | @UChicagoIBD @Georgetown GI trained | @ABC @AmCollegeGastro #YPLSP alum |tweets ≠ med advice

Denver, CO
Joined April 2019
Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)Photo by Joshua M. Steinberg, MD (@joshsteinbergMD)
My advanced IBD fellowship @UChicagoIBD prepared me for a fulfilling and dynamic career as an #IBD specialist. If you’re interested in pursuing an IBD fellowship, check out our @MondayNightIBD webinar 👇🏻
🌟Interested in #IBD? 🌟Considering an #IBDFellowship? 🎥This 🔥#MNIBDWebinar w PDs @GlassnerKerri @tqaziMD & IBD specialist @joshsteinbergMD is for you ! 🎯Define your goals & find the right fit 🎯Leverage your network/CV 🎯Opportunities in academia & private practice & more
3
4
41
7,890
Joshua M. Steinberg, MD retweeted
So excited to announce we are opening a position for an #IBD #Fellow at @MarylandGastro starting 7/2027! 🤝Join a team of🌟IBD GI, APP, PharmD, for a year of in-depth clinical training, research & mentorship! Let’s open the doors to your 💫career in IBD 📲DM me if interested
5
13
77
3,049
Joshua M. Steinberg, MD retweeted
Apply for the ACG Institute Emerging Leadership Program! Develop skills in communication, time management, growing your network, and building DEI on your team. Apply by November 23: ➡️ gi.org/elp #LeadershipYou #ELP #FutureofGI @anoushkaduaMD @MLongMD
4
1
10
2,806
Joshua M. Steinberg, MD retweeted
First thoughts on VERDICT ... pending publication of the full manuscript by @vipuljairath and colleagues. 672 pts with mod-sev UC randomised to 1 of 3 targets on a vedo-based algorithm (stepped up to q4w if needed), with central reading of endoscopy and histology: • G1: symptoms • G2: + endoscopic remission (MES 0–1) • G3: + histological remission (Geboes <2B.0) The primary outcome was time to a UC complication over up to 80 weeks from reaching the target. Mean age was 41, with eight years of disease, a Mayo score of 8.7, nearly two-thirds Mayo 3, almost half on steroids and a fifth after an advanced therapy. By week 48, 74% (G1), 56% (G2) and 52% (G3) had reached their targets. Treating to endoscopy made a huge difference: 22% of G1 had a UC complication, against 7% in G2 and 9% in G3. The primary comparison, histology (G3) against symptoms (G1), gave a hazard ratio of 0.33 (95% CI 0.17 to 0.67), and endoscopy against symptoms (G2 vs G1) gave 0.30 (0.14 to 0.64). In the Q&A, Vip said the effect was greater still at Mayo 0 (data not shown). About half the complications were rescue therapy for a flare; only one was an admission and none a colectomy. We don't know what happened to the patients who did not meet their targets, across all groups. But there was no clear additive benefit from histology: G3 vs G2 had a HR of 1.10 (0.45 to 2.69). Read that with one more number. 79% of group 2 (99 of 125) were also in histological remission when they reached their endoscopic target, so the groups were clinically similar and the comparison rested on about one in five. And endoscopy was read centrally. When it is, Mayo 0 is usually free of neutrophils: 84% in LUCENT and over 90% in QUASAR. Local reading is another matter. In OCTAVE, central readers confirmed only 38 to 46% of local Mayo 0 calls. We do not have the equivalent data on paired centrally read endoscopy plus histology in UC patients not on advanced therapy (as far as I know) - that might matter in the real world. We know histological inflammation carries long-term risk, including cancer. VERDICT covers only one to two years. Most of that long-term evidence comes from scoring old H&E slides, recut from paraffin blocks if needed. You can't go back and re-read an old endoscopy the same way. So ... with endoscopy read well, histology added nothing we could detect. In the clinic, where we read our own scopes, it may still catch what endoscopy misses. FINALLY ... in the debate on histology vs endoscopy we must not lose sight of just how important VERDICT is for treat-to-target in UC. It is very clear that treating to endoscopic healing makes a huge difference to important patient outcomes. Of course, I still want to know if calprotectin is a good enough proxy for the real world ... ok let's await the full paper!
5
32
1
108
13,129
Joshua M. Steinberg, MD retweeted
Obefazimod in UC: the phase 3 maintenance data, from two talks @my_ueg 580 people with moderate to severe ulcerative colitis who responded to 8 weeks of obefazimod, a once-daily oral medicine, were re-randomised for 44 more weeks. Placebo here meant stopping a drug that had just worked. It works. Clinical remission at week 52 was 39 percentage points higher than placebo on 25 mg and 40 points higher on 50 mg. It works across the secondary endpoints too. On endoscopic improvement, endoscopic remission (Mayo 0), histo-endoscopic mucosal improvement, steroid-free remission, sustained remission, clinical response and symptomatic remission, the delta over placebo ran from 31 to 53 points, every one at p<0.0001. It works with and without prior advanced-therapy (AT) failure. In AT-naive patients the delta in clinical remission was 45-48%; after AT failure it was 28-33%; smaller, but still large. And it was well tolerated. Serious adverse events were within 2 points of placebo on either dose, fewer people stopped for an adverse event on drug than on placebo, and there were no deaths. Two cancers outside the skin, both on 50 mg, were judged unlikely to be related. What next: @Abivax_ plans to file in the US by the end of 2026, and the full phase 3 paper(s) are still to come. The first Crohn's data, from the phase 2b ENHANCE-CD trial, are due in mid-2027.
11
19
8
131
12,356
Joshua M. Steinberg, MD retweeted
In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo. Full ANTHEM-UC trial results and Research Summary: nej.md/4hLHjhO
1
14
63
12,798
Joshua M. Steinberg, MD retweeted
It’s a #SWIFT move w #Emvistegrat in UC @silvio_silvio75 💊Once a day oral alpha4beta7 ✅higher clinical response & remission, higher histo & endo improvement on 200mg Emvi vs placebo 👇🏽 @my_ueg #UEGWeek
1
16
31
2,258
Joshua M. Steinberg, MD retweeted
Stride III presented by @DignassAxel at #UEGW26 👇🏻
1
15
1
47
2,485
Joshua M. Steinberg, MD retweeted
The #VERDICT is out for T2T in UC @my_ueg 🔺Vedo w step-up if target not achieved 🔑Take home message ⬇️UC complication if CS-free sympt+endo+histo remission vs sympt remission alone 🔑Endo remission = endo+histo remission ⚠️Our 🎯should be Mayo 0/ not Mayo 1 @vipuljairath
1
25
2
66
8,739
Joshua M. Steinberg, MD retweeted
The eagerly awaited STRIDE-3 updated treatment targets in IBD, unveiled by Alex Dignass at #UEGWeek 🚨🆕 1. Evidence summary 2. Treatment targets in IBD 3. Time to target in IBD 4. Changes and conclusions 📸: thelancet.com/journals/langa…
1
50
1
169
10,618
Joshua M. Steinberg, MD retweeted
Impressive long-term data #Obefazimod (miR-124) in UC @my_ueg @bruce_sands1 🏆After dose 50mg->25mg >80% clinical remission >70% endo remission Over > 3 yrs f/up ! 🏆Improvement stable regardless of prior exposure to advanced therapy Favorable safety profile #UEGWeek
2
24
5
111
13,488
Joshua M. Steinberg, MD retweeted
Risankizumab was the first p19 IL-23 blocker licensed for Crohn's, nearly three years ahead of guselkumab. But guselkumab arrived with subcutaneous induction from day one. That matters. Infusion suites are full, and in the US an iv start followed by subcut maintenance can mean two separate insurance approvals, where an all-subcut route needs one. AFFIRM is the sc induction data for risa. First shown by press release in March, the first congress presentation was last night - Millie Long at ACG in Nashville (along with updated press release). Silvio Danese presents the data at UEG on Monday at 16:00. The regimen is 720 mg subcutaneously at weeks 0, 2, 4 and 8, then 360 mg every eight weeks from week 12. Guselkumab's subcutaneous induction is 400 mg at weeks 0, 4 and 8 (then 100mg q8w or 200mg q4w maintenance). In 289 people with Crohn's disease, two-thirds of whom had already failed an advanced therapy, week 12 clinical remission was 55% v 30% and endoscopic response 44% v 14%, roughly where intravenous induction landed in ADVANCE. Endoscopic remission was 28% v 10%. The benefit was largest in patients new to advanced therapy, with endoscopic response of 61% v 15%, against 35% v 14% after advanced therapy failure. AbbVie expects FDA approval later this year, and the EMA has been reviewing it since August, so Europe will probably follow in 2027.
3
26
3
69
6,238
Joshua M. Steinberg, MD retweeted
In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo. Full ANTHEM-UC trial results: nej.md/4hLHjhO
7
35
6
79
21,490
Joshua M. Steinberg, MD retweeted
#Guselkumab leads to improvement in non-passable bowel stenoses in #crohnsdisease patients w inflammation at baseline in GALAXI and GRAVITY (IV and SQ induction). Gene expression markers showed correlation btw inflammation and fibrosis #ACG26 #DrDavidRubin
9
23
1,194
Joshua M. Steinberg, MD retweeted
Replying to @MLongMD
@MLongMD - reporting the RCT of SQ #risankizumab induction in #crohnsdisease (AFFIRM), 720 mg SQ q2 w ➡️ 360 mg q8 w; 66% bio-IR incl USTK failures: consistently positive efficacy endpoints through wk 24 with larger effect among bionaive #ACG26
7
3
20
3,139
Highlight of reviewing #IBD posters at #ACG2026: seeing a couple of promising up-and-comers present their exciting data. The future of GI is bright! 😉 @AmCollegeGastro @ibdgijami #MarlaDubinsky #AdamCheifetz
1
31
1,337
Joshua M. Steinberg, MD retweeted
Prof Millie Long @MLongMD reviewing consensus on managing #IBD during pregnancy at the postgrad course #ACG2026 @AmCollegeGastro @UmaMahadevanIBD
2
7
37
1,789
Joshua M. Steinberg, MD retweeted
Interested in getting trained in bowel ultrasound, finishing the training in one year and never taking weeks away from home and work? iUSCAN is now offering its one year IUS Training and certification curriculum to all clinicians (including practicing GIs, APPs, and fellows)
6
11
941
Joshua M. Steinberg, MD retweeted
Congratulations to Dr. David Rubin @IBDMD on receiving the prestigious Master of the American College of Gastroenterology (MACG) distinction! A truly well deserved recognition of your remarkable contributions to gastroenterology, leadership, mentorship, and dedication to our profession. So proud of you, David! 👏
3
3
32
1,160
Deeply honored to receive the @AmCollegeGastro International Leadership Award. I've always believed that medicine, education & leadership transcend borders 🌎 & our greatest impact comes thru relationships we build, knowledge we share & opportunities we create for others. Grateful to the ACG, friends, mentors, colleagues #GlobalGICommunity. Congrats to Dr David Fleischer, a privilege to share this honor with you! – at Sixteen Mile Stand, OH
11
8
1
73
2,086